Genetic testing proves beneficial in prescribing effective blood thinners

A new research paper funded in part by the National Heart, Lung and Blood Institute (NHLBI) shows a clear advantage of genetic testing in helping health care providers choose the appropriate anti-platelet drug. Testing helps determine if a patient carries genetic variants in CYP2C19 that cause loss of its function. These variants interfere with the body’s ability to metabolize and activate clopidogrel, an anti-platelet medication.

CTO 2021 Is Now an Online Event: CTO Connect

The Cardiovascular Research Foundation (CRF) has announced that the 2021 Chronic Total Occlusion (CTO) Summit will now take place as a virtual event called CTO Connect. It will take place online February 20-21, 2021.

The conference will feature live case transmissions performed by some of the world’s leading operators along with real-time analysis from world-class faculty members. Live and on-demand sessions will also highlight engaging case-based discussions, challenging cases, and the latest technical developments and refinements in CTO PCI.

Announcing the TCT Connect Late-Breaking Trials and Science

The Cardiovascular Research Foundation (CRF) has announced over 30 late-breaking trial and science presentations that will be reported at TCT Connect. TCT, the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place online October 14-18.

Registration for TCT Connect Now Open

The Cardiovascular Research Foundation (CRF) is pleased to announce that registration for the annual scientific symposium, TCT Connect, taking place online October 14-18, is free for all attendees and is now open.

TCT 2020 Is Now a Virtual Event: TCT Connect

The Cardiovascular Research Foundation (CRF) has announced that Transcatheter Cardiovascular Therapeutics (TCT) 2020 will now take place as a virtual event called TCT Connect. The event will take place online October 14-18, 2020 and feature live case-based transmissions from around the globe, late-breaking clinical trials and science, virtual training, and countless opportunities to learn and engage with the brightest minds in interventional cardiovascular medicine.

Precision medicine guides choice of better drug therapy in severe heart disease

Is personalized medicine cost-effective? Researchers have answered that question for one medical treatment, genotype-guided antiplatelet therapy for acute coronary syndrome patients with PCI. Their study uses pharmacogenomics and economic analysis of real-world clinical data.

Mayo Clinic study looks at changes in patient characteristics, outcomes for coronary revascularization over 14-year period

The most common type of heart disease ― coronary artery disease ― affects 6.7% of adults and accounts for 20% of 2 in 10 deaths of adults under age 65. The condition builds over time as inflammation and cholesterol-containing plaques settle in the heart’s arteries, where they can eventually cause narrowing and blockages that lead to a heart attack.